Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Phosphorus or phosphorus compound
Reexamination Certificate
2001-07-18
2004-02-17
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Phosphorus or phosphorus compound
C424S681000, C424S682000, C424S683000, C424S686000, C424S688000, C424S689000, C424S692000, C424S697000, C424S709000, C424S423000, C514S056000, C623S001430, C623S921000
Reexamination Certificate
active
06692772
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to methods of treating thrombosis, and more particularly to the use of magnesium to prevent conditions such as in-stent thrombosis.
2. Discussion of the Related Art
Coronary artery disease is one of the country's largest health concerns. According to the American Heart Association, this disease affects 13.5 million Americans. Almost a million of these people have experienced heart attacks. Still others have experienced angina, undergone coronary artery bypass surgery and/or had heart transplants. Others in the later, or more severe, stages of coronary artery disease are in varying stages of congestive heart failure.
Coronary artery disease, which has been linked with the increase in cholesterol and saturated fat in our diets, is treatable. One main symptom of coronary artery disease is the deposit of these fatty materials alongside a vessel wall such as an arterial wall. This results in the progressive narrowing of the lumen, and arteriosclerosis. Such deposits may be treated through a procedure called angioplasty. During angioplasty, the doctor inserts a catheter into an artery, typically a groin artery, and maneuvers the catheter up through the artery until the catheter is positioned at the site of the narrowing or obstruction caused by plaque. The plaque may then be flattened by inflating a balloon located around the tip of the catheter. As the balloon expands, it compresses the fatty deposits against the walls of the artery.
During this potentially lifesaving procedure, the doctor may insert a stent into die vessel at the site of the blockage. This small, typically metallic device helps to hold the vessel open and improves blood flow. This serves to relieve the symptoms of Coronary Artery Disease.
Unfortunately, stents do not provide an absolute solution to this problem. Restenosis, a narrowing of the passageway which may initiated by platelet adhesion and aggregation at the site of arterial injury, and thrombosis frequently occur at the site of the stent. “Thrombosis” describes the formation of a thrombus, or blood clot, inside a blood vessel. Thrombosis may be caused by the continuous stresses from blood flow over the stent. The longitudinal lumen of a stent usually, if not always, has an irregular surface or regions that protrude into the lumen that can produce a turbulent fluid flow. Alternatively, the thrombosis may be the result of a foreign body reaction to the stent. The formation of a blood clot within a blood vessel may cause tissue damage. Such a clot may be life threatening, particularly when it partially or completely blocks the flow of blood through a blood vessel. If thrombosis occurs as a result of the stent placement, a secondary procedure or a surgical bypass operation is required.
Products such as aspirin, dipyridamole and heparin are known in the art to dissolve such clots. While these products may eliminate the clot, they have the potential serious side effect of causing prolonged bleeding. Additionally, the effect of the administration of such products may only be reversed by the formation or addition of new platelets.
It is desired to be able to place a stent within a vessel through percutaneous transluminal delivery without the risk of in-stent thrombosis. Such stent placement without the risk of in-stent thrombosis would greatly increase the quality of life for many patients. Accordingly, a method to prevent the formation of in-stent thrombosis that is not detrimental to the patient is desired.
REFERENCES:
patent: 4182774 (1980-01-01), Welstead, Jr. et al.
patent: 5140012 (1992-08-01), McGovern et al.
patent: 5849338 (1998-12-01), Richardson et al.
patent: 6042849 (2000-03-01), Richardson et al.
patent: 6087373 (2000-07-01), Coburn et al.
patent: 6100297 (2000-08-01), Weglicki
patent: 6201028 (2001-03-01), Shiff et al.
patent: 00/45162 (2000-08-01), None
Roth, A. et al., “Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty: a clinical and angiographic evaluation in a randomized patient population,” European Heart Journal, vol. 15(9), 1994, pp. 1164-1173.*
Chemical Abstracts 138:44639 (2002).*
Medline Abstract, accession No. 2001681052 (2002).*
Medline Abstract, accession No. 2002088281 (2002).*
Medline Abstract, accession No. 2001408480 (2001).*
Ravn, H. B. et al., “Early administration of intravenous magnesium inhibits arterial thrombus formation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17(12), 1997, pp. 3620-3625.*
www.americanheart.org, Angioplasty, Percutaneous Transluminal Coronary (PTCA), Mar. 23, 2001.
S.D. Gertz et al., “Effect of Magnesium Sulfate on Thrombus Formation Following Partial Arterial Constriction: Complications for Coronary Vasospasm,” Magnesium, vol. 6, No. 5, pp. 225-235 (1987).
H-D Claus, “Zur Frage der Wirksamkeit einer Thromboembolieprophylaxe durch Magnesium bei der Kontakttherapie von Portio- und Korpuskarzinomen der Uterus mit Gammastrahlern,” Strahlentherapie, vol. 135, No. 3, pp. 291-294 (1968).
H.B. Ravn et al., “Magnesium Inhibits Platelet Activity—an infusion study in healthy volunteers,” Thrombosis and Haemostasis, vol. 75, No. 6, pp. 939-944 (1996).
Michael Shecter et al., “Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease,” American Heart Journal, 140:212-218 (Aug., 2000).
Vladimir Rukshin et al, “Intravenous Magnesium in Experimental Stent Thrombosis in Swine,” Arteriosclerosis, Thrombosis and Vascular Biology, 21:1544-1549 (Sep., 2001).
Kaul Sanjay
Shah Prediman K.
Cedars-Sinai Medical Center
Pak John
Pillsbury & Winthrop LLP
LandOfFree
Prevention of in-stent thrombosis and complications after... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of in-stent thrombosis and complications after..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of in-stent thrombosis and complications after... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3306401